Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

被引:179
作者
Li, Shuai [1 ,2 ,3 ]
Silvestri, Valentina [4 ]
Leslie, Goska [2 ]
Rebbeck, Timothy R. [5 ,6 ]
Neuhausen, Susan L. [7 ]
Hopper, John L. [1 ]
Nielsen, Henriette Roed [8 ]
Lee, Andrew [2 ]
Yang, Xin [2 ]
McGuffog, Lesley [2 ]
Parsons, Michael T. [9 ]
Andrulis, Irene L. [10 ,11 ]
Arnold, Norbert [12 ,13 ]
Belotti, Muriel [14 ,15 ]
Borg, Ake [16 ]
Buecher, Bruno [14 ,15 ]
Buys, Saundra S. [17 ,18 ]
Caputo, Sandrine M. [14 ,15 ]
Chung, Wendy K. [19 ,20 ]
Colas, Chrystelle [14 ,15 ]
Colonna, Sarah, V [17 ,18 ]
Cook, Jackie [21 ]
Daly, Mary B. [22 ]
de la Hoya, Miguel [23 ]
de Pauw, Antoine [14 ,15 ]
Delhomelle, Helene [14 ,15 ]
Eason, Jacqueline [24 ]
Engel, Christoph [25 ]
Evans, D. Gareth [26 ,27 ]
Faust, Ulrike [28 ]
Fehm, Tanja N. [29 ]
Fostira, Florentia [30 ]
Fountzilas, George [31 ,32 ]
Frone, Megan [33 ]
Garcia-Barberan, Vanesa [23 ]
Garre, Pilar [23 ]
Gauthier-Villars, Marion [14 ,15 ]
Gehrig, Andrea [34 ]
Glendon, Gord [10 ]
Goldgar, David E. [35 ]
Golmard, Lisa [14 ,15 ]
Greene, Mark H. [33 ]
Hahnen, Eric [36 ,37 ,38 ]
Hamann, Ute [39 ]
Hanson, Helen [40 ]
Hassan, Tiara [41 ]
Hentschel, Julia [42 ]
Horvath, Judit [43 ]
Izatt, Louise [44 ]
Janavicius, Ramunas [45 ,46 ]
机构
[1] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Parkville, Vic, Australia
[2] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England
[3] Monash Univ, Sch Clin Sci, Precis Med, Monash Hlth, Clayton, Vic, Australia
[4] Sapienza Univ Rome, Dept Mol Med, Rome, Italy
[5] Harvard TH Chan Sch Publ Hlth, Boston, MA USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] City Hope Natl Med Ctr, Dept Populat Sci, Beckman Res Inst, Duarte, CA USA
[8] Odense Univ Hosp, Dept Clin Genet, Odence, Denmark
[9] QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Brisbane, Qld, Australia
[10] Mt Sinai Hosp, Fred A Litwin Ctr Canc Genet, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[11] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada
[12] Christian Albrechts Univ Kiel, Univ Hosp Schleswig Holstein, Dept Gynaecol & Obstet, Campus Kiel, Kiel, Germany
[13] Christian Albrechts Univ Kiel, Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, Campus Kiel, Kiel, Germany
[14] Inst Curie, Serv Genet, Paris, France
[15] Paris Sci Lettres Res Univ, Paris, France
[16] Lund Univ, Dept Clin Sci Lund, Div Oncol & Pathol, Lund, Sweden
[17] Univ Utah Hlth, Dept Med v, Salt Lake City, UT USA
[18] Univ Utah Hlth, Huntsman Canc Inst, Salt Lake City, UT USA
[19] Columbia Univ, Dept Pediat, New York, NY 10027 USA
[20] Columbia Univ, Dept Med, New York, NY USA
[21] Sheffield Childrens Hosp, Sheffield Clin Genet Serv, Sheffield, S Yorkshire, England
[22] Fox Chase Canc Ctr, Dept Clin Genet, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[23] Hosp Clin San Carlos, IdISSC Inst Invest Sanitaria, Mol Oncol Lab, CIBERONC, Madrid, Spain
[24] Nottingham Univ Hosp NHS Trust, Nottingham Clin Genet Serv, Nottingham, England
[25] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany
[26] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol Sci,Div Evolut & Genom Sci, Manchester, Lancs, England
[27] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, St Marys Hosp, Manchester, Lancs, England
[28] Univ Tubingen, Inst Med Genet & Appl Genom, Tubingen, Germany
[29] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Dept Gynecol & Obstet, Dusseldorf, Germany
[30] Natl Ctr Sci Res Demokritos, Mol Diagnost Lab, INRASTES, Athens, Greece
[31] Aristotle Univ Thessaloniki, Sch Med, Thessaloniki, Greece
[32] German Oncol Ctr, Dept Med Oncol, Limassol, Cyprus
[33] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[34] Univ Wurzburg, Dept Human Genet, Wurzburg, Germany
[35] Univ Utah, Sch Med, Dept Dermatol, Huntsman Canc Inst, Salt Lake City, UT USA
[36] Univ Cologne, Fac Med, Ctr Familial Breast & Ovarian Canc, Cologne, Germany
[37] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[38] Univ Cologne, Fac Med, Ctr Integrated Oncol CIO, Cologne, Germany
[39] German Canc Res Ctr, Mol Genet Breast Canc, Heidelberg, Germany
[40] St George Hosp, Southwest Thames Reg Genet Serv, London, England
[41] Canc Res Malaysia, Breast Canc Res Programme, Subang Jaya, Selangor, Malaysia
[42] Univ Hosp Leipzig, Inst Human Genet, Leipzig, Germany
[43] Univ Munster, Inst Human Genet, Munster, Germany
[44] Guys & St Thomas NHS Fdn Trust, Clin Genet Dept, London, England
[45] Vilnius Univ, Fac Med, Inst Biomed Sci, Dept Human & Med Genet, Vilnius, Lithuania
[46] State Res Inst Ctr Innovat Med, Vilnius, Lithuania
[47] Inserm U900, Genet Epidemiol Canc Team, Paris, France
[48] Inst Curie, Paris, France
[49] Mines ParisTech, Fontainebleau, France
[50] Stanford Univ, Sch Med, Dept Epidemiol & Populat Hlth, Stanford, CA USA
基金
加拿大健康研究院; 澳大利亚国家健康与医学研究理事会;
关键词
ASCERTAINMENT SAMPLING PROBLEM; BREAST-CANCER; PROSTATE-CANCER; FAMILY-HISTORY; MUTATIONS; CARRIERS; OVARIAN; RESOLUTION;
D O I
10.1200/JCO.21.02112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE To provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management. METHODS We used data from 3,184 BRCA1 and 2,157 BRCA2 families in the Consortium of Investigators of Modifiers of BRCA1/2 to estimate age-specific relative (RR) and absolute risks for 22 first primary cancer types adjusting for family ascertainment. RESULTS BRCA1 PVs were associated with risks of male breast (RR = 4.30; 95% CI, 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach (RR = 2.17; 95% CI, 1.25 to 3.77) cancers. Associations with colorectal and gallbladder cancers were also suggested. BRCA2 PVs were associated with risks of male breast (RR = 44.0; 95% CI, 21.3 to 90.9), stomach (RR = 3.69; 95% CI, 2.40 to 5.67), pancreatic (RR = 3.34; 95% CI, 2.21 to 5.06), and prostate (RR = 2.22; 95% CI, 1.63 to 3.03) cancers. The stomach cancer RR was higher for females than males (6.89 v 2.76; P = .04). The absolute risks to age 80 years ranged from 0.4% for male breast cancer to approximately 2.5% for pancreatic cancer for BRCA1 carriers and from approximately 2.5% for pancreatic cancer to 27% for prostate cancer for BRCA2 carriers. CONCLUSION In addition to female breast and ovarian cancers, BRCA1 and BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, and prostate (only BRCA2 PVs) cancers, but not with the risks of other previously suggested cancers. The estimated age-specific risks will refine cancer risk management in men and women with BRCA1/2 PVs.
引用
收藏
页码:1529 / +
页数:14
相关论文
共 42 条
[1]   Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations [J].
Agalliu, Ilir ;
Gern, Robert ;
Leanza, Suzanne ;
Burk, Robert D. .
CLINICAL CANCER RESEARCH, 2009, 15 (03) :1112-1120
[2]  
[Anonymous], Consortium of Investigators of Modifiers of BRCA 1/2 (CIMBA)
[3]  
[Anonymous], International Agency for Research on Cancer website
[4]   The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions [J].
Antoniou, A. C. ;
Cunningham, A. P. ;
Peto, J. ;
Evans, D. G. ;
Lalloo, F. ;
Narod, S. A. ;
Risch, H. A. ;
Eyfjord, J. E. ;
Hopper, J. L. ;
Southey, M. C. ;
Olsson, H. ;
Johannsson, O. ;
Borg, A. ;
Passini, B. ;
Radice, P. ;
Manoukian, S. ;
Eccles, D. M. ;
Tang, N. ;
Olah, E. ;
Anton-Culver, H. ;
Warner, E. ;
Lubinski, J. ;
Gronwald, J. ;
Gorski, B. ;
Tryggvadottir, L. ;
Syrjakoski, K. ;
Kallioniemi, O-P ;
Eerola, H. ;
Nevanlinna, H. ;
Pharoah, P. D. P. ;
Easton, D. F. .
BRITISH JOURNAL OF CANCER, 2008, 98 (08) :1457-1466
[5]  
Antoniou AC, 2014, NEW ENGL J MED, V371, P1651, DOI [10.1056/NEJMoa1400382, 10.1056/NEJMc1410673#SA1, 10.1056/NEJMc1410673]
[6]  
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[7]  
Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365
[8]  
CANNINGS C, 1977, CLIN GENET, V12, P208
[9]   An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers:: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2(CIMBA) [J].
Chenevix-Trench, Georgia ;
Milne, Roger L. ;
Antoniou, Antonis C. ;
Couch, Fergus J. ;
Easton, Douglas F. ;
Goldgar, David E. .
BREAST CANCER RESEARCH, 2007, 9 (02)
[10]   Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021 [J].
Daly, Mary B. ;
Pal, Tuya ;
Berry, Michael P. ;
Buys, Saundra S. ;
Dickson, Patricia ;
Domchek, Susan M. ;
Elkhanany, Ahmed ;
Friedman, Susan ;
Goggins, Michael ;
Hutton, Mollie L. ;
Karlan, Beth Y. ;
Khan, Seema ;
Klein, Catherine ;
Kohlmann, Wendy ;
Kurian, Allison W. ;
Laronga, Christine ;
Litton, Jennifer K. ;
Mak, Julie S. ;
Menendez, Carolyn S. ;
Merajver, Sofia D. ;
Norquist, Barbara S. ;
Offit, Kenneth ;
Pederson, Holly J. ;
Reiser, Gwen ;
Senter-Jamieson, Leigha ;
Shannon, Kristen Mahoney ;
Shatsky, Rebecca ;
Visvanathan, Kala ;
Weitzel, Jeffrey N. ;
Wick, Myra J. ;
Wisinski, Kari B. ;
Yurgelun, Matthew B. ;
Darlow, Susan D. ;
Dwyer, Mary A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (01) :77-102